Ascentage Pharma (AAPG) board to review 2025 results and potential final dividend
Rhea-AI Filing Summary
Ascentage Pharma Group International has called a board meeting for March 25, 2026. At this meeting, the board plans to review and, if appropriate, approve the Group’s annual results for the year ended December 31, 2025 and consider declaring a final dividend. The notice also confirms the current composition of the board, including Chairman and Executive Director Dr. Yang Dajun and a mix of non-executive and independent non-executive directors.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of March 2026
Commission File Number: 002-023311
ASCENTAGE PHARMA GROUP INTERNATIONAL
(Translation of Registrant’s name into English)
68 Xinqing Road
Suzhou Industrial Park
Suzhou, Jiangsu
China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On March 13, 2026, Ascentage Pharma Group International (“Ascentage Pharma” or the “Company”) issued an announcement entitled, “Notice of Board Meeting”. A copy of the announcement is furnished as Exhibit 99.1 to this Report.
1
INDEX TO EXHIBITS
| Exhibit Number |
Exhibit Title | |
|
99.1 |
Announcement dated March 13, 2026 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ASCENTAGE PHARMA GROUP INTERNATIONAL | ||
| Date: March 13, 2026 | /s/ Dajun Yang | |
| Name: | Dajun Yang | |
| Title: | Chief Executive Officer | |
3
Exhibit 99.1
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
ASCENTAGE PHARMA GROUP INTERNATIONAL
亞盛醫藥集團
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6855)
NOTICE OF BOARD MEETING
The board of directors (the “Board”) of Ascentage Pharma Group International (the “Company”, together with its subsidiaries, collectively the “Group”) hereby announces that a meeting of the Board will be held on Wednesday, March 25, 2026, for the purpose of, among other things, considering and, if appropriate, approving the annual results of the Group for the year ended December 31, 2025 and considering the declaration of a final dividend, if any.
| By order of the Board | |
| Ascentage Pharma Group International | |
| Dr. Yang Dajun | |
| Chairman and Executive Director |
Suzhou, People’s Republic of China, March 13, 2026
As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon DazhongNote1 as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David SidranskyNote2, Ms. Marina S. Bozilenko, Dr. Debra Yu and Dr. Marc E. Lippman, MD as independent non-executive Directors.
| Notes: | 1. | Dr. Lu Simon Dazhong satisfy the independence requirements of the U.S. Securities and Exchange Commission and Nasdaq corporate governance requirements |
| 2. | Dr. David Sidransky is the Lead Independent Non-Executive Director of the Company. |